Related Experiment Video
Updated: Mar 3, 2026
09:36
Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
28.0K
Pediatric Obesity and Cardiometabolic Disorders: Risk Factors and Biomarkers.
E Levy1,2, A K Saenger3, M W Steffes3
1Department of Nutrition, University of Montreal, Montreal, Quebec, Canada.
EJIFCC
|April 26, 2017
Summary
Childhood obesity is a global health issue, increasing risks for serious conditions like type 2 diabetes and heart disease. This review explores genetic and environmental factors, discussing biomarkers for diagnosis and treatment.
Area of Science:
- Pediatrics
- Endocrinology
- Public Health
Background:
- Childhood obesity is a prevalent global health concern affecting both genders.
- It significantly increases the risk of developing insulin resistance, hypertension, hyperlipidemia, liver disorders, type 2 diabetes, and cardiovascular diseases.
Purpose of the Study:
- To review the relationship between childhood obesity and genetic/environmental factors.
- To discuss potential biomarkers for diagnosing, treating, and monitoring obesity-related complications in children.
Main Methods:
- Literature review focusing on genetic and environmental influences on childhood obesity.
- Analysis of current and emerging biomarkers for pediatric obesity management.
Main Results:
- Childhood obesity is multifactorial, influenced by a complex interplay of genetic predispositions and environmental exposures.
- Several biomarkers show promise for early detection, personalized treatment strategies, and effective follow-up of associated health issues.
Conclusions:
- Understanding the etiological factors of childhood obesity is crucial for effective intervention.
- Further research into the application and limitations of biomarkers is essential for combating the childhood obesity epidemic.
Related Concept Videos
01:24Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
01:30Coronary Artery Disease I: Introduction
1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
326
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
326
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
294
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
294
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
257
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
257
01:24Overview of Lipid Metabolism
6.1K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.1K